Opthea Ltd (OPTEY)

Opthea Ltd is an Australian clinical-stage biopharmaceutical company whose shares are represented on OTC Markets through an ADR depositary receipt structure under the ticker OPTE.Y. The company focuses on research and development programs built around therapies targeting vascular endothelial growth factors C, D, and R3. Its pipeline includes Sozinibercept, which is in phase 3 development for wet age-related macular degeneration and in phase 2 for diabetic macular edema. Opthea operates in the biotechnology and healthcare sectors, was formerly known as Circadian Technologies Limited, and adopted its current name in December 2015. Incorporated in 1984, the company is headquartered in Melbourne, Australia.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.